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Background: Thymoquinone (TQ) was shown to reduce tumor growth in several cancer models both in vitro and
in vivo. So far only a few targets of TQ, including protein kinases have been identified. Considering that kinases are
promising candidates for targeted anticancer therapy, we studied the complex kinase network regulated by TQ.
Methods: Novel kinase targets influenced by TQ were revealed by in silico analysis of peptide array data obtained
from TQ-treated HCT116wt cells. Western blotting and kinase activity assays were used to determine changes in
kinase expression patterns in colorectal cancer cells (HCT116wt, DLD-1, HT29). To study the viability/apoptotic effects of
combining the PAK1 inhibitor IPA-3 and TQ, crystal violet assay and AnnexinV/PI staining were employed. Interactions
between PAK1 and ERK1/2 were investigated by co-immunoprecipitation and modeled by docking studies. Transfection
with different PAK1 mutants unraveled the role of TQ-induced changes in PAK1 phosphorylation and TQ´s effects on
PAK1 scaffold function.
Results: Of the 104 proteins identified, 50 were upregulated ≥2 fold by TQ and included molecules in the
AKT-MEK-ERK1/2 pathway. Oncogenic PAK1 emerged as an interesting TQ target. Time-dependent changes in
two PAK1 phosphorylation sites generated a specific kinase profile with early increase in pPAKThr212 followed by
late increase in pPAKThr423. TQ induced an increase of pERK1/2 and triggered the early formation of an ERK
1/2-PAK1 complex. Modeling confirmed that TQ binds in the vicinity of Thr212 accompanied by conformational
changes in ERK2-PAK1 binding. Transfecting the cells with the non-phosphorylatable mutant T212A revealed an increase
of pPAKThr423 and enhanced apoptosis. Likewise, an increase in apoptosis was observed in cells transfected with both
the kinase-dead K299R mutant and PAK1 siRNA. Using structural modeling we suggest that TQ interferes also with the
kinase domain consequently disturbing its interaction with pPAKThr423, finally inhibiting MEK-ERK1/2 signaling and
disrupting its prosurvival function. pERK1/2 loss was also validated in vivo.
Conclusions: Our study shows for the first time that the small molecule TQ directly binds to PAK1 changing its
conformation and scaffold function. Because TQ affects the central RAF/MEK/ERK1/2 pathway, the combination of TQ
with targeted therapies is worth considering for future anticancer treatments.
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Colorectal cancer (CRC) affects yearly more than 1 mil-
lion people worldwide [1], therefore there is constant
need to achieve more effective cures. Over the recent
years naturally occurring compounds have received in-
creasing attention because of their anticancer effects [2].
Thymoquinone (TQ), the active compound extracted
from Nigella sativa, is a very promising anticancer drug,
whether used separately or in combination with conven-
tional medicines [2-7]. Interestingly, TQ was found to
have only limited toxicity to normal intestinal cells
in vitro [8] and not to affect the survival or body weight
of animals when used at doses up to 25 mg/kg in colo-
rectal cancer animal models [9,10]. Previous work docu-
mented TQ´s growth inhibitory and apoptosis triggering
effects on colon and other solid tumors such as uterine
sarcoma, breast, and pancreatic cancer in a dose- and
time-dependent manner [9,11-14]. Moreover, TQ was
shown to reduce tumor growth and to induce apoptosis in
various murine cancer models [5-7,10,15,16]. So far, the
anticancer mechanism of TQ is not fully understood;
however, several modes of action have been described de-
pending on the stimulus and the cellular context [2].
Protein kinases, the protagonists of phosphorylation,
commonly work in complex networks and have become
novel candidates for targeted therapy. There are a few
studies describing the involvement of TQ in the regula-
tion of kinases i.e. AKT1 [2] , JAK2 [17], JNK [8], IKKb
[18], ERK2 [8], CHEK1 [9] andPlk1 [19]. Most of these
kinases are frequently deregulated in colon cancer. In
the last 10 years several kinase inhibitors have been clin-
ically tested or are currently undergoing clinical trials in
targeted therapy [20]. Such therapy blocks the growth
and spread of cancer by specifically interfering with mol-
ecules affecting tumor cell proliferation and progression.
In colorectal cancer we have shown that kinases such as
c-Jun N-terminal kinase (JNK) and the prosurvival
extracellular-signal-regulated kinase (ERK) were acti-
vated under TQ treatment before the onset of apoptosis
[8]. The TQ resistance observed in HCT116 p53−/−
cells was associated with an upregulation of CHEK1, a
serine/threonine kinase cell cycle checkpoint mediator,
indicating an inefficient defense mechanism against TQ-
induced DNA damage when p53 is absent [9].
So far despite a few reports, the interaction of TQ with
the kinase network of colon cancer cells is only poorly
understood. Kinase signaling has been extensively inves-
tigated in the last decade and new techniques of quanti-
tative proteomics have been developed simplifying the
study of complex systems. Thus we performed a quanti-
tative phospho-proteomic analysis to identify new tar-
gets in TQ- treated HCT116wt colorectal cancer cells.
For the first time we show a direct binding of the plant
derived small molecule TQ to the PAK1/ERK1/2 kinasecomplex leading to conformational changes in protein
structures and consequently to apoptosis.
Results and discussion
Identification of new TQ targets by peptide array analysis
Kinome analysis allows the characterization and quanti-
fication of the phosphorylation profile of a given kinase
target under various experimental conditions. Using a
peptide array, the treatment of colorectal HCT116wt
cells with 40 μM TQ for 24 h led to the identification of
104 proteins with a significant phosphorylation upregula-
tion, among which were 50 proteins and kinases upregu-
lated by ≥2 fold (out of 1152 kinase substrate peptides).
Many of these proteins were previously described as TQ
targets (such as p21Cip1, p53, ERK or NFkB) verifying the
feasibility of the array data (Additional file 1: Table S1).
The analysis of the phosphorylation motifs of all 104 can-
didates (Figure 1A) showed that TQ had a propensity for
serine phosphorylation as well as an 80% probability to in-
duce phosphorylation of a neutral polar amino acid (S
group). In silico analysis revealed that the most influenced
pathways (Figure 1B) and networks (Figure 1C,1D) were
those involved in cancer, cell cycle, cell death, and survival
mechanisms. Moreover 24 of the top 50 candidate pro-
teins were grouped into the cancer-related networks “cyto-
skeleton”, “PI3K/AKT” and “Wnt signaling” (Table 1). The
Venn-diagram for the most relevant biological functions
identified 11 TQ-modulated proteins that are common in
apoptosis, proliferation, and inflammation pathways. Be-
sides the epigenetic marker CEBPB, the analysis included
key molecules in the AKT-MEK-ERK pathway, a central
signaling network for current targeted therapies (Figure 1E).
With a fold-change of 2.12, p21 protein (Cdc42/Rac)-acti-
vated kinase 1 (PAK1) was an appealing candidate consider-
ing its role in cell growth, invasion, cell migration, cell
survival, mitosis and cytoskeletal remodeling of cancer cells
[21,22]. Recently PAK1 was considered a novel subject for
targeted cancer therapeutic approaches [23]. Furthermore
for the first time, PAK1 has been identified as a TQ target.
An extensive pathway mapping of genes differentially phos-
phorylated by TQ at 24 h and subsequent pathway annota-
tion clustering resulted in 5 significant pathway based
clusters. It is interesting that PAK1 was mostly associated
with AKT1 and RAF1 (Table 2) in all the pathways in the
Annotation cluster3. The top 4 pathways obtained through
clustering approach (T-cell receptor signaling, angiogenesis,
MAPK and chemokine signaling) also included PAK1 mak-
ing it the target of our more detailed study of TQ action.
TQ effect on PAK1 phosphorylation
In HCT116wt cells, the TQ-induced activation of
pPAK1Thr212 observed in the array analysis was verified
by western blotting (Figure 2A). Although PAK1 has sev-
eral different phosphorylation sites, only PAK1Thr212 was
Figure 1 TQ induces the phosphorylation of a multitude of proteins. Whole cell lysates of HCT116wt cells treated with 40 μM TQ were
probed on PepChip Kinomics v2 peptide array. A. Consensus sequence logo obtained, via WebLogo version 3.3, of the identified protein
phosphorylation motifs by Pepscan. In the left panel, the phosphorylated amino acid is placed on the position 0 of the x-axis and the frequency
of the neighboring amino acids is represented on the y-axis. In the right panel, the amino acids probability is shown according to their polarity
(hydrophilic amino acids (R), hydrophobic amino acids (I) and neutral amino acids (S)). B. Top canonical pathways identified by IPA analysis system
of the candidate proteins. C. Function analysis of the different proteins and their scores grouped in networks. D. List of top biofunctions involving
the identified proteins with p-value <0.05. E. Venn diagram of the top 50 candidates (≥2 fold phosphorylation) belonging to one or more of the
most relevant cancer related biological functions: apoptosis, proliferation and inflammation. The 11 candidates common to all three groups are
listed in the red square.
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vestigated two other well-studied phosphorylation sites:
pPAK1Thr423 and pPAK1Ser144, by western blotting. Time-
dependent changes in the expression patterns of
pPAK1Thr212 and pPAK1Thr423 generated a specific kinase
profile at early and late time points after TQ exposure.
While pPAK1Thr212 showed a fast induction at 1 and 3 h,
pPAK1Thr423, found within the activation loop of PAK1, in-
creased at 24 h (Figure 2A). In contrast, pPAK1Ser144 and
total PAK1 levels did not change over time (Figure 2A). In-
vestigating another colorectal cancer cell line, DLD-1
showed the same profile of pPAK1Thr212 and pPAK1Thr423
regulation over time (Figure 2B). As expected, the TQ resist-
ant HT29 cells [8] showed a different kinase profile where
both pPAK1Thr212 and pPAK1Thr423 levels increased at the
same time from 3 to 6 h and decreased at 24 h (Figure 2C).TQ is a possible PAK1 inhibitor
To further understand the role of PAK1 in TQ-induced
apoptosis, we used 1,1′-disulfanediyldinaphthalen-2-ol
(IPA-3), the allosteric inhibitor of PAK1. IPA-3 prevents
pPAK1Thr423 phosphorylation by targeting the auto-
regulatory site and disrupting the functional interaction be-
tween PAK1 and Cdc42 in addition to inhibiting the activity
of other kinases [23,24]. Here we show that TQ did not
change the activity of AKT2, GSKα, GSKβ and p38, sug-
gesting that this molecule might be more specific than IPA-
3 in interacting with PAK1 (Additional file 2: Figure S1). In
addition, we performed a crystal violet viability assay and
obtained an IC50 of 141 μM ±30.7 in normal intestinal epi-
thelial HCEC cells in comparison to an IC50 of 50 μM±6
in HCT116 tumor cells (Additional file 3: Figure S2), thus
confirming the limited toxicity of TQ to normal cells.
Table 1 Identified TQ targets belonging to cancer-related pathways
Network Identified substrate Phospho site Prot ID Folds up (24 h)
Cytoskeleton EphB1 Y594 NP_004432 2.93
Lamin A/C S22 CAA27173 2.45
MAP2v S1679 NP_114034 2.30
Syntaxin 1A S14 NP_004594 2.22
Lamin B1 S395 NP_005564 2.12
SNAP23 T24 NP_003816 2.08
PI3K/AKT Lck S158 AAH13200 3.45
HSP22 S14 NP_0055180 3.32
PKR T451 NP_002750 3.92
Beta-2-adrenergic receptor-B2AR S262 NP_000015 2.80
AKT1 Y326 NP_005154 2.22
Bone marrow kinase BMX-ETK Y40 AAC08966 2.16
Glucocorticoid receptor S211 NP_000167 2.15
PAK1 T212 AAC24716 2.12
Nitric oxide synthase 1 S852 NP_000611 2.09
CHOP S79 NP_004074 2.08
Metabotropic glutamate receptor 1 T695 AAA87843 2.05
RAF1-c-RAF S43 NP_002871 2.00
Wnt Beta-catenin Y142 NP_001895 2.89
T-cell transcription factor 4 S60 NP_110383 2.59
N-myc S263 NP_005369 2.43
L1 cell adhesion molecule S1152 NP_000416 2.25
APC S2054 NP_000029 2.06
MAP3K7-TAK1 S192 NP_663304 2.01
Table 2 Pathway mapping of TQ-phosphorylated targets by Annotation cluster3
Database Pathway p-Value Genes identified by peptide array
KEGG_PATHWAY T cell receptor signaling pathway 0.001971 PDK1, AKT1, RAF1, PAK1*, MAP3K7
PANTHER_PATHWAY Angiogenesis 0.008722
AKT1, TCF7L2, APC, RAF1, PAK1, CTNNB1,
NOS1
KEGG_PATHWAY MAPK signaling pathway 0.041478 MAX, AKT1, RAF1, PAK1, MAP3K7
KEGG_PATHWAY Chemokine signaling pathway 0.042726 AKT1, CCR2, RAF1, PAK1
KEGG_PATHWAY Renal cell carcinoma 0.053539 AKT1, RAF1, PAK1
PANTHER_PATHWAY Ras Pathway 0.054889 AKT1, RAF1, PAK1, MAP3K7
BIOCARTA Influence of Ras and Rho proteins on G1 to S Transition 0.055681 AKT1, RAF1, PAK1
KEGG_PATHWAY ErbB signaling pathway 0.079412 AKT1, RAF1, PAK1
KEGG_PATHWAY Focal adhesion 0.091138 AKT1, RAF1, PAK1, CTNNB1
KEGG_PATHWAY Fc gamma R-mediated phagocytosis 0.093575 AKT1, RAF1, PAK1
BIOCARTA MAPKinase Signaling Pathway 0.094598 MAX, RAF1, PAK1, MAP3K7
PANTHER_PATHWAY
Inflammation mediated by chemokine and cytokine signaling
pathway
0.229979 AKT1, CCR2, RAF1, PAK1, MAP3K7
PANTHER_PATHWAY T cell activation 0.27141 AKT1, RAF1, PAK1
*PAK1 is given in bold letters.
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Figure 2 TQ induces the phosphorylation of pPAKThr212 and pPAKThr423 in several colorectal cell lines. HCT116wt A, DLD-1 B, and HT29 C.
cells were treated with 40 μM TQ and collected after 1, 3, 6 and 24 hours. Untreated cells were used as control. Whole cell lysates were immunoblotted
against total PAK1, pPAKThr212, pPAKThr423 and pPAKSer144 (only for HCT116wt). Blots were then probed with GAPDH for loading control. Data shown
are representative of two independent experiments.
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HCT116wt cells were pre-incubated with IPA-3 for 1 h
and then stimulated with 40 μM TQ (Figure 3). Crystal
violet staining showed that 30% of the cells were dead
after 10 μM IPA-3 (Figure 3A). Interestingly, the combin-
ation of TQ and IPA-3 (10 μM) caused significantly more
cell death and decreased cell viability by 70% (Figure 3A).
AnnexinV/PI staining revealed that most dead cells were
in late apoptosis (Figure 3B). TQ induced the “apoptotic”
cleavage of PARP (89 kDa fragment) at 24 h, whereas in
response to IPA-3 the cleavage was stronger and occurred
earlier at 6 h (Figure 3C). Furthermore, transfection with
kinase-dead dominant negative K299R mutant led to a lar-
ger increase in PARP cleavage showing more apoptosis
when the kinase activity is lost (Figure 3D). Similarly,
PAK1 siRNA transfection of cells followed by TQ treat-
ment induced an increase in the pro-apoptotic response
(Figure 3E).
In a next step, we determined changes in the expres-
sion of the different phosphorylation sites of PAK1 in
IPA-3 and/or TQ treated cells (Figure 3F). As expected,
pPAK1Thr423 protein level decreased when IPA-3 was
combined with TQ at 3 and 6 h but this decrease was
not sustained at 24 h. To further understand this find-
ing, we modeled the interaction between IPA-3, PAK1
and TQ. Docking IPA-3 to PAK1 (Additional file 4: Fig-
ure S3A) revealed that IPA-3 binds to the CRIB motif
(75–90) in the autoregulatory region of PAK1 dimer in a
mode that enhances the interaction between both mono-
mers (binding site first monomer: His83 and Gly98, sec-
ond monomer: Met99). When TQ is docked into the
IPA-3-bound conformation, IPA-3 still binds with bothmonomers. TQ also interacts with residues of both
PAK1 monomers in the auto-inhibited dimer conform-
ation (Additional file 4: Figure S3B and Additional file 5:
Table S2). In this binding mode, TQ interaction with the
kinase inhibitory segment of PAK1 (Asn38 residue) pos-
sibly causes the masking of the PAK1 activation loop
and prevents the action of IPA-3 on Thr423 (Additional
file 4: Figure S3).
The phosphorylation of pPAK1Thr212 in TQ and IPA-3
co-treated cells showed a remarkable increase in com-
parison to TQ alone (Figure 3F). This was surprising
considering that IPA-3 only interrupts the interaction
between Cdc42 and the autoregulatory site at Thr423
residue of PAK1 [24,25]. Knowing that pPAK1Thr212 is a
major target of ERK2 [26], we further studied the role of
ERK1/2/PAK1 interaction in response to TQ.
TQ triggers conformational changes in PAK1 and induces
ERK1/2-PAK1 binding
In a next step we investigated the effect of TQ on ERK1/2
in HCT116wt cells. Kinase activity assay revealed that
ERK1/2 activity significantly increased after 1 h of TQ treat-
ment (Figure 4A). This was confirmed by western blotting,
where pERK1/2 level was elevated at the same time point
followed by a later decrease to normal levels (Figure 4B). In
addition to the previously published increase in TUNEL
and cleaved caspase-3 [10], immunohistochemical staining
of the prosurvival pERK1/2 was significantly (p < 0.05) lost
in the nuclei of the TQ treated tumor xenografts (Figure 4C
and Additional file 6: Figure S4).
Furthermore, time course analysis of pPAKThr212 and
pERK1/2 levels at early time points revealed that pPAKThr212
Figure 3 Combining TQ and the PAK inhibitor IPA-3 increases apoptosis. A. HCT116wt cells, pretreated with different concentrations of
IPA-3 (1-50 μM) alone or with TQ 40 μM for 24 hours, were stained with crystal violet dye and assessed for viability. Data are presented as percentage of
control. *indicates a p-value < 0.001 when comparing IPA-3 treatment to IPA-3 + TQ treatment. Each value is the mean ± SD of three independent
experiments each done in quadruplicates. B. Cells pretreated with 10 μM IPA-3 for one hour followed by 24 hours incubation with 40 μM TQ were
collected and analyzed by flow cytometry for a double AnnexinV/PI staining. The percentage of the different cell populations was calculated by FlowJo
software. C. Cells were pretreated for 1 hour with 10 μM IPA-3 and then incubated with 40 μM TQ. Cell pellets were collected after 1, 3, 6, 24 and 48 hours.
Lysates were blotted against PARP and GAPDH for loading control. D. PARP cleavage was detected in endogenous (left blots) and kinase-dead dominant
negative PAK1 K299R mutant transfected HCT116 wt cells (right blots) after 24 hours of 100 μM TQ. Higher TQ concentration was used in all transfection
experiments due to the high cell density. E. Cells were transfected with PAK1 siRNA or scrambled (SCR) siRNA and checked for PAK1 knockdown by
western blotting. PARP cleavage was detected in endogenous and PAK1 siRNA transfected cells after 24 hours of 60 μM TQ. SCR siRNA was used as
transfection control. GAPDH was used as loading control. F. Cell lysates were immunoblotted against pPAKThr212, pPAKThr423 and total PAK1. GAPDH was
used as a loading control. Data shown are representative of two independent experiments.
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pERK1/2 increase started after 45 min of TQ treatment
(Additional file 7: Figure S5). This suggests an involve-
ment of other kinases in the phosphorylation of PAK1 at
the Thr212 site in response to TQ. Interestingly, co-
immunoprecipitation studies showed that TQ induced the
formation of a PAK1 and ERK1/2 complex (Figure 4D).
To better understand the nature of ERK1/2/PAK1 inter-
action in response to TQ, we modeled the PAK1-TQ
interaction by docking PAK1 and TQ and identified a
possible ligand binding site at the vicinity of Thr212
(Figure 5A) with a docking score of −2.316 (Additional
file 5: Table S2) [27-30]. The energy of ERK2 bound to
PAK1 conformation changed in the presence of TQfrom -21883 kcal/mol to −22076 kcal/mol suggesting
that TQ strengthens ERK2 binding to PAK1 [31]. It
may also be noted from Figure 5B and Figure 5C that
ERK2 binds in a different mode to PAK1 in the pres-
ence of TQ. ERK2 binding to a different conformation
of PAK1 may prevent ERK2 from phosphorylating the
Thr212 of PAK1. This could explain why pPAK1Thr212
levels decrease over time in response to TQ (Figure 2A).
Furthermore, TQ-induced pERK1/2 levels were not re-
duced by IPA-3 treatment, instead ERK1/2 activity was
further enhanced from 1 h to 6 h when TQ was combined
with IPA-3 (Figure 4B), suggesting the involvement of
other upstream kinases in phosphorylating ERK1/2. If the
TQ-triggered closer binding between ERK1/2 and PAK1 is
Figure 4 (See legend on next page.)
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Figure 4 TQ induces early upregulation of ERK1/2 and the formation of a PAK1-ERK1/2 complex. A. TQ treated cells were assessed for
ERK1/2 activity. Data is presented as fold activity normalized to control activity. Each value is the mean ± SD of two independent experiments
each done in duplicates. B. Cells pretreated for 1 hour with 10 μM IPA-3 were incubated with 40 μM TQ and cell pellets were collected after 1, 3, 6 and
24 hours. Lysates were immunoblotted for pERK1/2 and total ERK1/2. GAPDH was used as loading control. C. Box plot analysis of the percentage of
tumor cells expressing nuclear pERK1/2 in mouse xenografts after TQ treatment. n represents the number of investigated mouse tissues in each group.
*5 corresponds to a sample outlayer. D. Cell lysates stimulated with 60 μM TQ for 10, 45 minutes, 1 and 24 hours were immunoprecipitated for PAK1
(upper panel) and ERK1/2 (lower panel) and blotted against total PAK and ERK1/2. IgG bands were used as loading control. Data shown are
representative of two independent experiments. E. Cells transfected with the PAK1wt vector and the T423E mutant vector were exposed to 24 hours
of 100 μM TQ. 30 μg of proteins was immunoblotted against pERK1/2. *indicates the omission of intermediate samples. F. Cells transfected or not with
T212A and T212E mutants of PAK1 were treated with 100 μM TQ. Lysates were immunoblotted against pPAKThr423. Data shown are representative of
two independent experiments. G. Model of PAK1 activation (in dark blue) and catalytic loop (purple) presenting the different amino acids of interest. The
kinase domain in PAK1 (residues 249–545) is where T423 resides. H. Model of PAK1 activation (in dark blue) and catalytic loop (purple) in the presence of
TQ showing rearrangements in the main activation loop under TQ. There are additional hydrogen bonds in the catalytic loop region involving residues
Arg388 and Arg421 which are known to interact with Thr423 for the catalytic activity.
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crease in pPAK1Thr212 levels when TQ is combined with
IPA-3 (Figure 3F).
From these findings we propose a functional relation
between both phosphorylation sites of PAK1. Indeed,
T212A mutant induced a significant increase in
pPAK1Thr423 levels whereas the hyperphosphorylated
T212E mutant showed a lesser extent of increase
(Figure 4E). As presented in Additional file 5: Table S2,
TQ binds in the vicinity of Thr212 and no binding occurs
next to the 423 site. Therefore we speculate that the chain
reaction orchestrated by TQ starts at Thr212 site, which
correlates with the western blot pattern (Figure 2A). Fur-
thermore, T423E resulted in a decrease in ERK1/2 phos-
phorylation (Figure 4F) suggesting an impaired interference
of Thr423 residue with the kinase domain of PAK1 under
TQ treatment. We analysed the structural changes induced
by TQ on PAK1 catalytic site and activation loop. Figure 4G
and Figure 4H depict the structural conformation of the
catalytic domain of PAK1 in the absence (Figure 4G) or
presence of TQ (Figure 4H). The kinase domain shows a
root-mean-square deviation of 0.38 Å accompanied by re-
arrangements in the main activation loop. Hydrogen bond
analysis (Additional file 8: Table S3) showed that a higher
number of hydrogen bonds are formed in the catalytic loop
region in the presence of TQ involving residues Arg388
and Arg421 which are known to interact with Thr423 for
the catalytic activity. Finally this results in a disturbed inter-
action between the Thr423 site and the catalytic kinase do-
main which inhibits the PAK1 kinase activity and its
prosurvival signaling (Figure 6). There are three other
lines of evidence for this hypothesis: first, early TQ-
induced ERK1/2 activation is inhibited when PAK1Thr423
is maximally phosphorylated at 24 h. Second, when IPA-3
is combined with TQ there is a decrease in Thr423 phos-
phorylation at early time points accompanied by a signifi-
cant upregulation of pERK1/2 levels that confirms an
early activation of MEK-ERK signaling. The lack of inhib-
ition of pPAK1Thr423 at 24 h is closely associated with adecrease in prosurvival ERK1/2 activation and enhanced
apoptosis induction at 24 h. This can be explained by an-
other structural modeling showing that TQ has the ability
to effectively bind to the autoregulatory domain of PAK1
preventing IPA-3 ability to interrupt the interaction be-
tween Cdc42 and pPAK1Thr423. Third, the pPAK1Thr212
upregulation is not as dramatic as the pERK1/2 activation
after combined TQ and IPA-3 treatment reinforcing the
inhibitory loop for PAK1 activation. Although pERK1/2
should disappear completely by the higher level of
pPAK1Thr423 at 24 h, it is worth mentioning that other
secondary kinase loops could be at play. Consequently the
phosphorylation status of Thr423 and PAK1 kinase activ-
ity is affected by TQ proving the experimental observa-
tions reported here.Conclusions
PAK1 has been described as a scaffold for ERK1/2/MEK
to recruit MEK to RAF at the membrane [32] thus facili-
tating signaling through the ERK1/2 pathway [26,33].
We have shown previously a prosurvival function of
ERK1/2 under TQ, since inhibition of ERK1/2 by the
MEK inhibitor PD98059 resulted in enhanced apoptosis
[8]. In the present study and for the first time we docu-
ment that a small natural molecule, TQ, directly binds
to PAK1/ERK kinase complex, induces considerable con-
formational changes of PAK1 and interrupts its scaffold
function. Upon TQ the interference of Thr423 phos-
phorylation with the kinase domain is disrupted inhibit-
ing the PAK1 kinase activity and its prosurvival signaling
[23]. TQ-induced loss of ERK1/2 dependent phosphoryl-
ation at Thr212 of PAK1 provides another negative feed-
back of prosurvival PAK1/MEK/ERK1/2 signaling. The
loss of nuclear pERK1/2 in TQ-treated mouse xenografts
confirms the in vivo relevance of our finding. Overall,
our approach allowed an identification of several novel
TQ targets which could be used in the future to evaluate
the therapeutic benefit of combination therapies.
Figure 5 TQ binds to PAK1 in the vicinity of Thr212. A. Surface representation of possible active conformation of PAK1 bound to TQ in the
vicinity of pPAK1Thr212. TQ is represented in stick (purple). PAK1 residues within the 4 Å interface of the binding site are labelled in red. The kinase
domain and the regulatory domain of PAK1 are marked in green and blue respectively. B. Surface representation of the PAK1-ERK2 complex. PAK1 and
ERK2 are shown in green and cyan respectively. Position of Thr212 is highlighted in red. C. Surface representation of PAK1-ERK2 complex in the presence
of TQ. Positions of Thr212 and TQ are highlighted in red and purple respectively.
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Cell lines and reagents
Human colon carcinoma HCT116wt, DLD-1 and HT29
cells were grown in RPMI 1640 medium (PAA Labora-
tories GmbH, Pasching Austria) supplemented with 10%
fetal bovine serum (FBS) and 1% penicillin-streptomycin
(PANTM Biotech GmbH, Germany) and kept at 37°C in
a humidified incubator (95% air, 5%CO2). Cells were
treated at 50% confluency with 40 or 60 μM TQ (Sigma-
Aldrich) dissolved in DMSO (final concentration lessthan 0.1%) and collected at different time points. PAK1
inhibition was performed by preincubating the cells with
10 μM IPA-3 (Sigma-Aldrich) for 1 hour.
Peptide Array PepChip Kinomics v2
HCT116wt cells (1.5x105/ml) were treated with 40 μM
TQ and collected after 24 hours. Proteins were extracted
and shipped to manufacturer (Pepscan, Netherland) ac-
cording to manufacturer protocol. Briefly, cell pellets
were lysed (20 mM Tris–HCl (pH 7.5), 150 mM NaCl,
Figure 6 TQ induces changes in the PAK1-ERK1/2 complex conformation inhibiting the prosurvival role of PAK1. A. Without TQ, in
cancer cells, ERK2 phosphorylates pPAK1Thr212 (I). While an interaction between pPAK1Thr212 and pPAK1Thr423 is so far not reported (II), pPAK1Thr423
is known to induce the catalytic activity of PAK1 (III) thus leading to the activation of the prosurvival ERK1/2 pathway (IV). B. Upon TQ we
observed massive conformational changes of PAK1 disrupting its scaffold function in prosurvival PAK1/MEK/ERK1/2 signaling and leading to the
following modified signaling: ERK1/2-PAK1 binding is reinforced preventing pPAK1Thr212 phosphorylation by ERK1/2 (I). This leads to an increased
phosphorylation at the Thr423 site (II) which impairs the interference with the catalytic domain of PAK1 and prevents PAK1 activation (III) finally
resulting in apoptosis induction (IV).
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dium pyrophosphate, 1 mM beta-glycercophosphate,
1 mM sodium orthovanadate (Na3VO3), 1 mM NaF,
Roche Complete protease inhibitor cocktail). After sonic-
ation, the lysates were spin down and snap frozen before
being shipped to the manufacturer. The concentration of
the samples was determined using Bradford Protein Assay
(Bio-Rad, Hercules, CA). Samples were then hybridized
on PepChip Kinomics v2 chip and the kinome profiling
was performed by the Pepscan Company. The peptide
array was done with samples obtained from two inde-
pendent experiments and every sample was spotted two
times on the array.
Array Analysis software Ingenuity pathway analysis (IPA)
Peptide array data was analyzed by Ingenuity pathway
analysis software (IPA, version 9.0, Ingenuity © Systems,
www.ingenuity.com, Mountain View, CA, USA). Thedata set contained upregulated proteins (fold-change ≥ 2
after 24 hours of 40 μM TQ treatment) identified by the
pepscan peptide array and their protein ID number. Stat-
istical significance of the different pathways obtained by
IPA was calculated using a right-tailed Fisher’s Exact test
[34]. Pathways with a p–value ≤ 0.05 were selected.
WebLogo v3 application (http://weblogo.threeplusone.
com/) was used to analyze the phosphorylation consen-
sus motifs of all the kinases and proteins identified by
the array.
Pathway Annotation Clustering
The probable pathways by which the 50 candidate pro-
teins, with fold-change ≥ 2 after 24 hours of 40 μM TQ
treatment, could interfere were predicted using DAVID
bioinformatics tool (http://david.abcc.ncifcrf.gov) [35, 36].
For pathway mapping, Uniprot IDs of differentially phos-
phorylated proteins were submitted to the DAVID web
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Human Protein Atlas (http://www.proteinatlas.org/) as
background. Pathway predictions were made by in-
cluding the subset pathway databases: KEGG, Panther,
Biocarta, Reactome and BBID followed by pathway an-
notation clustering.
Western blotting
HCT116wt, DLD-1 and HT29 cells were grown to 50%
confluency and treated with 40 μMTQ and harvested
over different time points. The cells were then lysed with
RIPA lysis buffer (150 mM NaCl, 0.5% DOC, 0.1% SDS,
1% NP40, 50 mM Tris pH8) containing a cocktail of
protease inhibitors. The protein concentration of all
samples was determined by by DC BioRad protein assay
kit (BioRad Laboratories, Hercules, CA) using bovine
serum albumin as standard. Total proteins (50 μg /sam-
ple) were separated on an 8–12% SDS polyacrylamide gel
and transferred to nitrocellulose membrane by blotting.
After blocking with 5% non-fat dry milk in TBST buffer,
membranes were incubated with primary antibody at 4°C
overnight, washed three times, with TBST buffer, and in-
cubated again with the corresponding HRP-conjugated
secondary antibody at room temperature for 1 h. The
membranes were then washed with TBST buffer and pro-
tein bands were detected by enhanced chemilumines-
cence. PAK1, ERK1/2, pERK1/2 and PARP were
purchased from Cell signaling; pPAKThr212 and pPAKSer144
from Abcam and pPAKThr423 from Abgent. Densitometric
analysis was performed for all western blots using ImageJ
1.45 s software.
Immunoprecipitation
Cells treated with 60 μM TQ for 10, 45, 60 minutes and
24 hours were collected and lysed using RIPA buffer
supplemented with proteases and phosphatases inhibi-
tors. Immunoprecipitiation was performed using the
Dynabeads Protein G magnetic separation KIT as per
manufacturer protocol (Invitrogen). After incubating the
beads with 600 μg of proteins, they were incubated with
anti-PAK1 and anti-ERK1/2 antibodies. The precipitated
lysates were then loaded into SDS-PAGE gels and
immunoblotted against total PAK1 and ERK1/2.
Plasmids and siRNA transfections
Plasmids (PAK1wt, K299R, T212E, T212A, T423E) were
a gift from Prof. Jonathan Chernoff (Fox Chase Cancer
Center, 333 Cottman Avenue, Philadelphia). Cells seeded
in 6-well plates were transfected at 90% confluency with
1 μg of the different plasmids for 6 hours, using Invitro-
gen Lipofectamine 2000 according to manufacturer in-
structions. Afterwards cells were treated with 100 μM
TQ (due to the high cellular density) and collected after24 hours. Cell lysates were then used for Western blotting
analysis.
PAK1 and scrambled siRNA reagents were purchased
from Thermo Fisher Scientific (Dharmacon RNAi Tech-
nologies). Lipofectamine RNAiMAX reagent was used to
transfect HCT116 cells with 10 μM siRNA, according to
manufacturer’s instructions. The next day the trans-
fected cells were split and 50% confluent plates were
treated with 60 μM TQ. Cell lysates were then used for
Western blotting analysis.
Structural analysis by docking
To understand the interaction between PAK1 and TQ,
we modeled the structure of PAK1 and performed mo-
lecular docking with TQ using the Schrodinger suite
(Maestro, version 9.3, Schrodinger, Inc, New York, NY,
2012). A model of the possible active state conformation
of PAK1 was obtained by integrating the available crystal
structures of the autoinhibitory domain 78-147(PDB ID:
1F3M) [27] and the kinase domain 250-542(PDB ID:
3Q52) [28] of PAK1 and a threaded model of the region
corresponding to 148–249 using ITASSER [29,30]. The
possible ligand binding sites in PAK1 was analyzed using
the SiteMap module (SiteMap, version 2.6, Schrödinger,
Inc., New York, NY, 2012) of the Schrodinger suite. In
order to analyze the binding mode of TQ near to Thr212
site, grids were generated focusing on Thr212 site and the
interacting residues were identified. To study the interaction
details of PAK1 and ERK2, the crystal structure of ERK2
available with PDB ID:2ERK [31] was docked to the TQ
bound and unbound conformations of PAK1 using ClusPro
[37,38]. The energies of the complexes were determined
through energy minimization using AMBER11 [39] . Crystal
structure of the autoinhibited dimer of PAK1 (PDB ID:
1F3M) was used to understand the binding mode of IPA-3
on PAK1 [29]. The structural coordinates of the residues
(416–422), missing in the PDB, belong to the kinase activa-
tion segment of PAK1 and were modeled using Model-
ler9v12 [40] . IPA-3 was then docked to the autoregulatory
region of PAK1 (autoinhibited conformation). To analyze
the combined effect of TQ and IPA-3 on PAK1, TQ was
docked to the IPA-3 bound conformation of PAK1. All the
dockings were performed using the extra precision mode of
the Glide program of Schrodinger (Glide, version 5.8, Schrö-
dinger, Inc., New York, NY, 2012). The structures of TQ
and IPA-3 were obtained from the PubChem database. Pro-
tein and ligand structures for docking were prepared using
Protein Preparation Wizard and LigPrep utilities of Schro-
dinger (LigPrep, version 2.5, Schrödinger, Inc., New York,
NY, 2012). All renderings were done using Chimera 1.8 [41].
Kinase Activity assay
Multi-kinase ELISA array was performed as per the manu-
facturer protocol (Symansis). Briefly, Cells treated with
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with 1X denaturing cell lysis buffer (Symansis CLB001).
30 μg of proteins were loaded on pre-coated strips with
antibodies corresponding to the investigated kinases. After
several washing and hybridization steps, absorbance of
each well was measured at 450 nm using VICTORTM X3
multilabel reader.
Cell Viability assay
Cellular viability was measured by crystal violet staining.
HCT116wt (3.75 × 104/ml) cells were seeded in 96 well
plate and treated with 40 μM TQ and/or 1-50 μM IPA-3
for 24 hours. The treated cells were washed once with PBS,
fixed for 15 min in a crystal violet solution (0.5% crystal
violet in 20% methanol) at room temperature, then washed
twice with water and air-dried. The stained cells were solu-
bilized with methanol for 15 min with mild agitation. Ab-
sorbance was measured at 595 nm using VICTORTM X3
multilabel reader. IC50 values were calculated using EXCEL
2010. Statistical analysis was performed using SPSS version
19. One tailed Student T-Test was performed by compar-
ing 2 samples assuming that they have equal variances.
Annexin V/Propidium Iodide staining
Apoptosis was measured using Annexin V/PI co-staining.
HCT116wt cells (1.5 × 105/ml) were pretreated with IPA-
3 (10 μM) for 1 hour then treated with TQ (40 μM) for
24 hours. After collection, cells were centrifuged at 200 g
for 5 min, 4°C and washed with 1X PBS. The pellet was
resuspended in 100 μl Annexin-V-Fluos labeling solution
(10 μl annexin reagent and 10 μl PI solution in 150 μl in-
cubation buffer (according to manufacturer, Roche). The
samples were incubated for 7 min in the dark, at room
temperature then 100 μl incubation buffer was added. The
cellular fluorescence was then measured using a Fluores-
cence Activated Cell Sorter (FACS) flow cytometer
(BDFACS CantoTM II). Each sample was collected as
20,000 ungated events and the different cell populations
were determined using FlowJo software (FlowJo7.6.5).
Immunohistochemistry
Immunohistochemistry (IHC) was performed on available
paraffin fixed tissue blocks from a xenograft experiment
[10] to detect the expression of pERK1/2. Rehydration of
tissue sections was performed in descending concentrations
solutions of ethanol (96% to 70%). Antigen was retrieved by
heating in a pressure cooker (1 mmol/L Tris-EDTA buffer,
120°C, 5 min). The slices were incubated in blocking solu-
tion (Dako, Glostrup, Denmark) to prevent nonspecific
binding sites. Next pERK1/2 (1:2000) primary antibody was
added to the slices and incubated for 30 min at room
temperature. The sections were then washed with washing
buffer (Dako) and incubated with EnVision + System horse-
radish peroxidase-linked secondary antibody (goat anti-rabbit, Dako) at room temperature for 30 min. Positive im-
munoreactivity was detected using diaminobenzidine +
(Dako). Positive and negative IHC controls were included
in this study. Percentage and intensity of positively stained
epithelial cells (cytoplasmic versus nuclei) was quantified
and scored by an expert pathologist (T.T.R.). Statistical ana-
lysis was performed using SPSS. Two tailed student t-test
was performed by comparing 2 samples assuming that they
have equal variances.Additional files
Additional file 1: Table S1. Known TQ targets identified by the
peptide array.
Additional file 2: Figure S1. TQ did not induce changes in the main
kinases affected by IPA-3. Cells treated with 40 μM TQ were collected
after 1, 3, 6 and 24 hours. Untreated cells were used as a control. 30 μg
of proteins per well were used to assess the activity of AKT2, GSKα, GSKβ
and p38. Data is presented as fold activity normalized to control activity.
Each value is the mean ± SD of two independent experiments each done
in duplicates.
Additional file 3: Figure S2. TQ show low toxicity on normal intestinal
cells. HCT116 (A) and HCEC (B) cells were treated with different TQ
concentrations (0-100 μM) for 24 hours to define the IC50 value. Cell
viability was assessed by crystal violet staining. Data are presented as
percentage of control. Each value is the mean ± SD of three independent
experiments done in quadruplicates.
Additional file 4: Figure S3. IPA-3 and TQ bind to the autoinhibited
dimer conformation of PAK1. A. Model of IPA-3 bound autoinhibited dimer
conformation of PAK1 (PDB id:1kx5). Autoregulatory region (blue and green)
and kinase domain (pink and blue) of PAK1 dimer are shown. IPA-3 is shown
in red using a stick representation and the residues interacting with IPA-3
labeled in black. B. Model of IPA-3 and TQ bound autoinhibited dimer
conformation of PAK1. TQ is shown in purple as a stick representation. The
residues interacting with TQ are labeled in black. The rendering follows color
legend used in A.
Additional file 5: Table S2. PAK1 residues interference with TQ and/or
IPA-3.
Additional file 6: Figure S4. TQ induces down regulation of prosurvival
pERK1/2 in vivo. Mouse xenograft experiment showing A.
Immunohistochemical detection of pERK1/2 on tumors of control (left)
and TQ treated (right) animals. B. Box plot analysis of the percentage of
tumor cells expressing cytoplasmic pERK1/2 after TQ treatment. n
represents the number of investigated mouse tissues in each group. *16
corresponds to sample 16 being an outlayer.
Additional file 7: Figure S5. TQ induces the phosphorylation of
pPAK1Thr212 before the phosphorylation of pERK1/2. Cells treated with
60 μM TQ were collected after 10, 15, 30, 45, 60 and 90 min. untreated
cells were used as control. 30 μg of proteins were immunoblotted
against pPAKThr212 and pERK1/2. GAPDH was used as loading control.
Data shown are representative of two independent experiments.
Additional file 8: Table S3. Hydrogen bonds formed at the PAK1
catalytic site in the absence and presence of TQ.Abbreviations
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